GM-CSF in Patients With Pulmonary Alveolar Proteinosis
Status:
Terminated
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is a study to determine the efficacy and safety of granulocyte-macrophage
colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with
pulmonary alveolar proteinosis (PAP).